I-MAB (IMAB) Stock Forecast & Price Target

Compare

385 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IMAB Analyst Ratings

Moderate Buy

2 Buy

0 Hold

0 Sell

Based on 2 analysts giving stock ratings to

I-MAB

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IMAB Stock 12 Month Forecast

Average Price Target

$6.50

▲(44.44% Upside)

Based on 2 Wall Street analysts offering 12 month price targets for I-MAB in the last 3 months. The average price target is $6.50 with a high forecast of $7.00 and a low forecast of $6.00. The average price target represents a 44.44% change from the last price of $4.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","-1":"-$1","1.25":"$1.25","3.5":"$3.5","5.75":"$5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.25,3.5,5.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.62,2.956923076923077,3.293846153846154,3.630769230769231,3.9676923076923076,4.304615384615385,4.641538461538461,4.978461538461539,5.315384615384616,5.6523076923076925,5.989230769230769,6.326153846153846,6.663076923076924,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.62,2.9184615384615387,3.216923076923077,3.5153846153846153,3.813846153846154,4.112307692307692,4.4107692307692306,4.7092307692307696,5.007692307692308,5.306153846153846,5.604615384615385,5.903076923076923,6.201538461538462,{"y":6.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.62,2.88,3.14,3.4000000000000004,3.66,3.92,4.18,4.44,4.7,4.96,5.220000000000001,5.48,5.74,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.8,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.85,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.79,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.62,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$7.00

Average Price Target$6.50

Lowest Price Target$6.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andres Y. Maldonado

H.C. Wainwright

Buy

55.56%

Upside

Reiterated

08/21/25

Analysts Are Bullish on Top Healthcare Stocks: Santhera Pharmaceuticals Holding (SPHDF), I-MAB (IMAB)

Gil Blum

Needham

$5→$6

Buy

33.33%

Upside

Reiterated

08/20/25

I-MAB's Positive Outlook: Buy Rating Backed by Financial Stability and Promising Clinical Developments5:35 PM 2025 PRICE TARGET & ESTIMATE CHANGE Biotechnology I-MAB Sponsored ADR (IMAB) RATING BUY PRICE TARGET $6.00 from $5.00 PREV CLOSE $4.21 52-WEEK RANGE $0.60 - $5.90 2Q:25 Update; Givastomig Expansion Cohort on Track for 1Q:26, Target to $6 Givastomig (giva) dose expansion results (N=40) remain on track for 1Q:26 and will help determine next steps for the program. A randomized Phase II is expected, however, details will only be provided following expansion cohort update. We believe recent financing removes a potential overhang from the stock and are increasing our Target to $6 to reflect increased value for givastomig. Dose escalation results for giva + nivo + chemo at ESMO GI showed encouraging activity in 1L GC patients across a broad range of CLDN18.2/PD-L1 expression (note).

Christopher Liu

Lucid Capital

Buy

11.11%

Upside

Initiated

05/28/25

I-Mab initiated with a Buy at Lucid CapitalI-Mab initiated with a Buy at Lucid Capital

Kumaraguru Raja

Brookline Capital Markets

Buy

33.33%

Upside

Initiated

02/27/25

I-Mab initiated with a Buy at BrooklineI-Mab initiated with a Buy at Brookline

Dex Genotek

TR | OpenAI - 4o

―

Hold

―

Reiterated

01/31/25

AI Generated ArticleAI Generated Article

Joseph Catanzaro

Piper Sandler

Buy

77.78%

Upside

Reiterated

09/16/24

Piper Sandler reiterates Overweight Rating on I-Mab (IMAB)Piper Sandler analyst Joseph Catanzaro reiterated an Overweight rating and $8.00 price target on I-Mab (NASDAQ: IMAB).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andres Y. Maldonado

H.C. Wainwright

Buy

55.56%

Upside

Reiterated

08/21/25

Analysts Are Bullish on Top Healthcare Stocks: Santhera Pharmaceuticals Holding (SPHDF), I-MAB (IMAB)

Gil Blum

Needham

$5→$6

Buy

33.33%

Upside

Reiterated

08/20/25

Christopher Liu

Lucid Capital

Buy

11.11%

Upside

Initiated

05/28/25

I-Mab initiated with a Buy at Lucid CapitalI-Mab initiated with a Buy at Lucid Capital

Kumaraguru Raja

Brookline Capital Markets

Buy

33.33%

Upside

Initiated

02/27/25

I-Mab initiated with a Buy at BrooklineI-Mab initiated with a Buy at Brookline

Dex Genotek

TR | OpenAI - 4o

―

Hold

―

Reiterated

01/31/25

AI Generated ArticleAI Generated Article

Joseph Catanzaro

Piper Sandler

Buy

77.78%

Upside

Reiterated

09/16/24

Piper Sandler reiterates Overweight Rating on I-Mab (IMAB)Piper Sandler analyst Joseph Catanzaro reiterated an Overweight rating and $8.00 price target on I-Mab (NASDAQ: IMAB).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering I-MAB

1 Month

xxx

Success Rate

7/18 ratings generated profit

Average Return

+5.49%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 38.89% of your transactions generating a profit, with an average return of +5.49% per trade.

3 Months

xxx

Success Rate

6/18 ratings generated profit

Average Return

+31.01%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of +31.01% per trade.

1 Year

Gil BlumNeedham

Success Rate

6/18 ratings generated profit

Average Return

+54.20%

reiterated a buy rating 9 days ago

Copying Gil Blum's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +54.20% per trade.

2 Years

xxx

Success Rate

10/18 ratings generated profit

Average Return

+105.92%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 55.56% of your transactions generating a profit, with an average return of +105.92% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IMAB Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IMAB has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IMAB average Analyst price target in the past 3 months is 6.50.

Each month's total comprises the sum of three months' worth of ratings.

IMAB Financial Forecast

IMAB Earnings Forecast

Next quarter’s earnings estimate for IMAB is -$0.04 with a range of -$0.10 to -$0.02. The previous quarter’s EPS was -$0.03. IMAB beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.22% of the time in the same period. In the last calendar year IMAB has Outperformed its overall industry.

IMAB Sales Forecast

Next quarter’s sales forecast for IMAB is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. IMAB beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.92% of the time in the same period. In the last calendar year IMAB has Preformed in-line its overall industry.

IMAB Stock Forecast FAQ

What is IMAB’s average 12-month price target, according to analysts?

Based on analyst ratings, I-MAB’s 12-month average price target is 6.50.

What is IMAB’s upside potential, based on the analysts’ average price target?

I-MAB has 44.44% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IMAB a Buy, Sell or Hold?

I-MAB has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.

What is I-MAB’s price target?

The average price target for I-MAB is 6.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $7.00 ,the lowest forecast is $6.00. The average price target represents 44.44% Increase from the current price of $4.5.

What do analysts say about I-MAB?

I-MAB’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.

How can I buy shares of IMAB?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

I-MAB (IMAB) Stock Forecast & Price Target

IMAB Analyst Ratings

IMAB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering I-MAB

IMAB Analyst Recommendation Trends

IMAB Financial Forecast

IMAB Earnings Forecast

IMAB Sales Forecast

IMAB Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts